Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus
Open Access
- 14 September 2017
- Vol. 9 (9), 255
- https://doi.org/10.3390/v9090255
Abstract
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated in 2012, and circulated worldwide with high mortality. The continual outbreaks of MERS-CoV highlight the importance of developing antiviral therapeutics. Here, we rationally designed a novel fusion inhibitor named MERS-five-helix bundle (MERS-5HB) derived from the six-helix bundle (MERS-6HB) which was formed by the process of membrane fusion. MERS-5HB consists of three copies of heptad repeat 1 (HR1) and two copies of heptad repeat 2 (HR2) while MERS-6HB includes three copies each of HR1 and HR2. As it lacks one HR2, MERS-5HB was expected to interact with viral HR2 to interrupt the fusion step. What we found was that MERS-5HB could bind to HR2P, a peptide derived from HR2, with a strong affinity value (KD) of up to 0.24 nM. Subsequent assays indicated that MERS-5HB could inhibit pseudotyped MERS-CoV entry effectively with 50% inhibitory concentration (IC50) of about 1 μM. In addition, MERS-5HB significantly inhibited spike (S) glycoprotein-mediated syncytial formation in a dose-dependent manner. Further biophysical characterization showed that MERS-5HB was a thermo-stable α-helical secondary structure. The inhibitory potency of MERS-5HB may provide an attractive basis for identification of a novel inhibitor against MERS-CoV, as a potential antiviral agent.Keywords
This publication has 35 references indexed in Scilit:
- Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine DevelopmentJournal of Virology, 2013
- A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoVVirology Journal, 2013
- Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4Cell Research, 2013
- Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome CoronavirusThe Journal of Infectious Diseases, 2010
- Human Immunodeficiency Virus Type 1envClones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing AntibodiesJournal of Virology, 2005
- Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory SyndromeThe New England Journal of Medicine, 2003
- Protein Design of an HIV-1 Entry InhibitorScience, 2001
- LearnCoil-VMF: computational evidence for coiled-coil-like motifs in many viral membrane-fusion proteinsJournal of Molecular Biology, 1999
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences of the United States of America, 1994
- HIV-1 inhibition by a peptideNature, 1993